Molecular diagnostics consumable growth rates, particularly oncology and infectious disease testing volumes in clinical labs
Pharma/biotech R&D spending trends affecting Life Sciences segment demand for sample prep kits and NGS workflow products
New product launch momentum for QuantiFERON-TB, QIAstat-Dx syndromic testing, and liquid biopsy assays with associated reimbursement approvals
Instrument placements (QIAsymphony, QIAcube Connect) driving future consumable pull-through at 3-5x instrument revenue over lifecycle
moderate - Clinical diagnostics revenues (~40% of total) exhibit defensive characteristics tied to healthcare utilization rather than GDP, though elective testing volumes can fluctuate. Life Sciences segment shows higher cyclicality linked to pharma/biotech R&D budgets and academic grant funding, which contract during recessions. Applied Testing (forensics/food safety) is relatively stable. Overall, 60% revenue exposure to research markets creates moderate GDP sensitivity.
Rising rates create modest headwinds through two channels: (1) Biotech funding environment tightens, reducing customer R&D budgets and delaying instrument purchases, particularly impacting Life Sciences segment growth. (2) Higher discount rates compress valuation multiples for med-tech growth stocks trading at 15-20x EBITDA. However, minimal direct impact given low debt/equity of 0.44x and limited refinancing risk. Rate increases above 5% historically correlate with 10-15% biotech VC funding declines.
Technology disruption from next-generation sequencing cost declines potentially commoditizing sample preparation workflows, with Illumina vertical integration and Oxford Nanopore direct-from-sample sequencing bypassing traditional extraction steps
Reimbursement pressure in molecular diagnostics as payers scrutinize high-cost genetic testing, particularly in oncology panels where $3,000-5,000 test prices face coverage restrictions
Regulatory pathway complexity for companion diagnostics requiring parallel FDA/EMA approvals with pharma partners, creating 3-5 year development timelines and approval risk
value - Stock trades at 15x EBITDA versus 20-25x for high-growth diagnostics peers, attracting value investors seeking stable cash flows and modest growth. Defensive healthcare exposure with 4.5% FCF yield appeals to quality-focused funds. Limited dividend (reinvestment in R&D prioritized) reduces income investor appeal. Institutional ownership concentrated among healthcare specialists recognizing consumable recurring revenue model.
Trend
-14.7% vs SMA 50 · -27.4% vs SMA 200
Momentum
Heavy distribution on elevated volume — institutions appear to be exiting. Squeeze setups unlikely while selling pressure persists.
Based on volume distribution analysis. Direct short interest data (short float %, days to cover) is not available in current data sources.
ANALYST ESTIMATES
Analyst consensus estimates · Actuals replace estimates as reported
| Year | Revenue Est. | Rev Gth | EPS Est. | EPS Gth | Range | Analysts |
|---|---|---|---|---|---|---|
FY2025 | $2.1B $2.1B–$2.1B | — | $2.39 | — | ±6% | High12 |
FY2026(current) | $2.1B $2.1B–$2.2B | ▲ +3.5% | $2.44 | ▲ +1.9% | ±3% | High11 |
FY2027 | $2.3B $2.2B–$2.3B | ▲ +5.3% | $2.64 | ▲ +8.2% | ±4% | High12 |
Dividend per payment — last 6 periods
INSTITUTIONAL OWNERSHIP
QGEN News
About
qiagen is the leading global provider of sample to insight solutions to transform biological materials into valuable molecular insights. qiagen sample technologies isolate and process dna, rna and proteins from blood, tissue and other materials. assay technologies make these biomolecules visible and ready for analysis. bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. automation solutions tie these together in seamless and cost-effective molecular testing workflows. qiagen provides these workflows to more than 500,000 customers around the world in molecular diagnostics (human healthcare), applied testing (forensics, veterinary testing and food safety), pharma (pharmaceutical and biotechnology companies) and academia (life sciences research). as of june 30, 2015, qiagen employed approximately 4,400 people in over 35 locations worldwide. further information can be found at http://www.qiagen.com.
| Symbol | Price | Day % | Mkt Cap↓ | P/E | Rev Grw | Margin | ELO |
|---|---|---|---|---|---|---|---|
QGEN◀ | $32.98 | -0.93% | $6.8B | 17.0 | +565.1% | 2032.9% | 1500 |
| $404.35 | -3.20% | $2.1T | 30.5 | +3296.8% | 4510.0% | 1500 | |
| $132.58 | -6.05% | $307.9B | 20.7 | -44.8% | 1012.0% | 1500 | |
| $88.38 | -2.58% | $303.7B | 13.6 | +318.8% | 1510.7% | 1500 | |
| $148.08 | -1.13% | $282.6B | 21.0 | +597.3% | 2564.4% | 1500 | |
| $181.58 | -1.83% | $281.6B | 26.9 | +862.9% | 1745.9% | 1500 | |
| $183.40 | -0.23% | $256.1B | 16.8 | +213.3% | 1482.4% | 1500 | |
| Sector avg | — | -2.28% | — | 20.9 | +829.9% | 2122.6% | 1500 |